Author: ifox

Five Reasons to Put Clarity Gold on the Top of Your Watchlist

Top FIVE Reasons Clarity Gold Corp. (CSE: CLAR) Could be the Biggest Mover in 2020!

Once in a while as an investor, the stars align perfectly, we all remember our war stories, hitting it big, investing in Tesla when it was trading at $200 or investing in Wheaton Precious Metals when it was way undervalued at $10. Also, we remember those moments, where we felt it in our gut, to invest in a stock and we allow fear to take hold and we never acted on it. Today, we are overly excited to bring you, quite possibly, your chance at redemption!

We have been watching Clarity Gold for months as it has had an incredible rise from just $.22 cad to $1.05 cad in a little over just one month. That is 377% gains and upon further research, we can see exactly why this company has a rocket ship trajectory. Normally, a company has a few, maybe three, really incredible talking points of why it could be an incredible investment. Not with Clarity, we have FIVE exciting attributes that make us believe that Clarity Gold Corp. (CSE: CLAR) could very well be a great pick in 2020!

1. Technical traders, the chart is one of the best we have seen in a long time!
2. Gold is at $2000!
3. Their holdings are showing incredible promise for not only gold, but copper and molybdenum.
4. Fundamental traders say the management team is the Who’s Who of exploration!
5. As we all know, the old adage, what have you done for me lately, their deal flow is the envy of the industry.

The Chart is a trader’s dream!

There is no need for a technical analysis of this chart, even a child, could see that this could be headed to the moon. However, it is worth noting, the news they have released which created this bullish trend line.

On June 26, 2020, Clarity Gold Corp. completed its initial public offering, resulting in 16.95 million common shares outstanding That is a very tiny float for a company this size. This is a truly a ground floor opportunity with possibly massive potential.

On July 6, 2020, they announced the acquisition of two gold projects and the expansion of the Empirical Project. A week later, on July 15, 2020, Clarity announced that they mobilized field crews to the Tiber and Gretna Green projects. Following that announcement, they issued press stating the mobilization of an exploratory team to the empirical project on July 22, 2020.

All of this news could be pointing toward a huge announcement. Consequently, the stock has been on an absolute rampage ever since the initial public offering. We cannot wait to see what’s on the horizon for Clarity Gold Corp.

Gold Just Hit $2,000, an ALL-TIME record HIGH!

The exploration of gold, is possibly, the hottest sector to invest in at the moment. Not only is $2000 an ounce a record high, it was trading at just $400 per ounce in 2005. That is 400% growth with no end in sight. Take into account, the current global pandemic, civil unrest and lack of confidence in fiat currency, gold is position to take over the world.

Peter Schiff and Jim Rickards just said could gold go to $15,000?

Gold pushed above its all-time record price last week. Where does it go from here? Featured on Kitco News Bugs Peter Schiff and Jim Rickards appeared to talk about gold’s trajectory and the possibility of $15,000 in the future.

Peter was shocked that gold took this long to break through.

“A lot has happened in the last decade. We’ve certainly printed a lot of money.”

Peter said the Federal Reserve has moved into a policy from which it can never extricate itself.

Rickards brought up something commodity trader Jim Rogers told him several years ago. Gold is going to the moon, but nothing goes to the moon without a 50% correction along the way. Between gold’s high in 2011 and its low in 2015, it fell about 50%.

“OK, that’s your 50% retracement. Now, that’s the bottom. Now it’s going up and the sky’s the limit.”

Peter said, “We’ve now formed a very solid base between $1,200 and $1,500.”

“Now I think we’ve broken out of that range. I think we’ve taken out the highs. I think it’s another leg of the bull market. I don’t think there’re going to be any significant pullbacks from here. I mean, there’ll be pullbacks, but I don’t think they’re going to be very significant. I think if you’re waiting for a big drop to buy gold, you’re going to wait a long time.”

Rickards agreed, saying the retracement is over. Peter said waiting to buy gold in hope of a higher price is foolish.

“The world is going to be full of people who are waiting to buy gold and who are broke because they didn’t just bite the bullet and buy it.”

Peter said ultimately the world is going to sever its relationship with the dollar. It will go off the dollar standard and back on the gold standard.

“And I think this is going to be a more precipitous drop in the dollar’s value than it was in the 70s, so we could see something equally impressive in the price of gold.”

Rickards was willing to put a number on how high he thinks gold could go. He projected $15,000 gold by 2025. He extrapolated some data to make his point. And he showed that given the M1 money supply in dollars, euros, pounds, yen and yuan – if you divide it by the official amount of gold, you get about $15,000 per ounce.

Could these projects be the reason why the market is so interested in Clarity Gold?

Clarity Gold has three projects they are currently exploring:

1. Tyber – as described on their website, “Contains a number of separate but apparently related quartz vein systems hosted in shear and fracture zones”.
2. Gretna Green – One historic selected sample assayed 00 grams per tonne gold, 51.43 grams per tonne silverand 17.8 per cent copper (Minister of Mines Annual Report 1921).
3. Empirical Project – GOLD and more gold, this is the most promising holding, so we are going to focus on this project.

Empirical Project

Target Commodities: Gold, Copper, and Molybdenum

Project Area: 10,518 Ha

Ownership:

• 5,117 Ha 100% Clarity Gold Corp.
• 5,401 Ha option to earn 100%

Location: 12km south of Lillooet, British Columbia, Canada

For those of our fellow investors that are familiar with our work digging up hidden gems, pardon the pun, you are aware that this is not the first time we featured a gold exploration company. Upon reviewing the news and website, we became excited for the historical drill intercepts found on the Empirical Project. The above image was captured from Clarity Gold’s website and to give you a crash course on gold exploration, under the results column you will notice 21m @ 3.67 g/t Au which in lay terms, represents the mineralization density, in even more lay terms, how much GOLD is in the ground. Research shows that 1.5-5 g/t Au represents medium grade, which is good! Anything over 5 g/t AU represents high grade mineralization, that is even better! The fact that the Empirical Project has had a 10.27 g/t Au is possibly why they are attracting so much attention. The management team has been very successful in projects exploring for gold, silver and copper and they have built their reputations by pulling together historic data and furthering advancing this work.

The management team is a fundamental trader’s dream!

James Rogers | Director, CEO

James is a resource professional and entrepreneur active in the exploration and mining sector for over 13 years, and has developed projects in the Americas, Europe, and Africa. Mr. Rogers is the Principal of Longford Exploration Services. Since 2017, James and his teams have identified and vended over 90 resource properties to public and private companies.

Andrew Male | Director​

Mr. Male is an experienced Director & Executive Officer of public and private companies in the resource and investment sectors. A former Founder and CEO of a TSX Venture Exchange Top 50 Company Ranked 9th, Mr. Male guided the company through the initial financing phases, project acquisitions, deployment of exploration programs, development financing, transitioning mining assets from greenfield to brownfield and the acquisition of adjacent producers and eventual sale to Private Equity.

Theo Van Der Linde | Director

Theo Van Der Linde is a Chartered Accountant with 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange and Canadian Securities Exchange (CSE) listed companies over the past several years. Industry experience includes financial services, manufacturing, oil & gas, mining and retail industries.

Ian Graham | Advisor

Mr. Graham has over 20 years of experience in the development and exploration of mineral projects, corporate transactions, project evaluations, and exploration.

Mr. Graham’s experience is mostly at major mining companies, namely Rio Tinto and Anglo American, including as Chief Geologist with the Project Generation Group at Rio Tinto. He has been involved with evaluation and pre-development work on several projects in Canada and abroad, including Resolution Copper (Arizona, USA), Diavik Diamond Mine (Northwest Territories, Canada), Eagle Nickel (Michigan, USA), Lakeview Nickel (Minnesota, USA) and Bunder Diamonds (India).

Clarity is exploring 3 different projects, what is next for the management team?

The management team at clarity gold has a pedigree of being at the right place at the right time. In their combined 50+ years of exploration and hundreds of projects it is very possible that the three projects they are currently working on is just the tip of the iceberg! They have built their careers on identifying profitable projects through geophysics, historical data, proprietary mining techniques and a dedication to the next project!

In conclusion, we are very optimistic in regards to the future for Clarity Gold Corp.

• Gold is at historic highs!
• In June of this year Clarity Gold Corp (CSE: CLAR) had its IPO where it went from $.22 cad to over $1.00 cad, this is a ground floor opportunity
• The chart shows a bullish trendline that could be positioning for a break out.
• The historical drilling records reveal a high potential for mineralization of Gold!
• The management team has over 50 years combined experience identifying and extracting elements
• Did we mention, Gold just hit 2,000 an ounce? Jim Rickards just announced that he believes gold could go to $15,000 an ounce.

Upon completion of our research we are extremely excited to encourage all investors to keep a close eye on Clarity Gold Corp. (CSE: CLAR), put it on your watch list today!

https://claritygoldcorp.com/

Disclaimer :This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on ​​CLAR (and / or any other mentioned companies and / or securities), and read this disclaimer in its entirety.Small Cap Exclusive profiles are not a solicitation or recommendation to buy, sell or hold securities. ​​Small Cap Exclusive is a paid advertiser and is not offering securities for sale. Neither ​​Small Cap Exclusive nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by ​​Small Cap Exclusive its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.Small Cap Exclusive does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.Information presented by Small Cap Exclusive may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.THIS SITE IS PROVIDED BY SMALL CAP EXCLUSIVE ON AN “AS IS” AND “AS AVAILABLE” BASIS. ​SMALL CAP EXCLUSIVE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, ​SMALL CAP EXCLUSIVE DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. SMALL CAP EXCLUSIVE DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM ​SMALL CAP EXCLUSIVE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. ​SMALL CAP EXCLUSIVE, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS. By using ​Small Cap Exclusive, you agree, without limitation or qualification, to be bound by, and to comply with, these Terms of Use and any other posted guidelines or rules applicable.The website contains links to other related World Wide Web Internet sites and resources. ​Small Cap Exclusive is not responsible for the availability of these outside resources, or their contents, nor does ​Small Cap Exclusive endorse nor is ​Small Cap Exclusive responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall ​Small Cap Exclusive be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.You agree to indemnify and hold ​Small Cap Exclusive, its officers, directors, owners, agents and employees, harmless from any claim or demand, including reasonable attorneys fees, made by any third party due to or arising out of your use of the website, the violation of these Terms of Use by you, or the infringement by you, or other user of the website using your computer, of any intellectual property or other right of any person or entity. We reserve the right, at our own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification.​Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).We publish the Information on our website, smallcapexclusive.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, Clarity Gold Corp., Inc. Small Cap Exclusive has been hired by Clarity Gold Corp for a period beginning on August 10, 2020 to publicly disseminate information about (CLAR) via website and email. We have been compensated $25,000. We will update any changes to our compensation.Third Parties paying us to market the Profiled Issuer we believe intend to sell their shares they hold while we tell investors to purchase during the Campaign. ​​Clarity Gold Corp. is a penny stock that was illiquid (little to no trading volume) prior to our Campaign, and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.No securities commission or other regulatory authority in Canada or any other country or jurisdiction has in any way passed upon this information and no representation or warranty is made by to that effect. The information is not a substitute for independent professional advice before making any investment decisions. The CSE (Canadian Securities Exchange) has not reviewed the information in this Article and does not accept responsibility for the adequacy or accuracy of it.​Small Cap Exclusive, reserves the right, at its sole discretion, to change, modify, add and/ or remove all or part of this Disclaimer and / or Terms of Use at any time.

Is Sorrento Therapeutics Inc (NASDAQ:SRNE) a Safe Biotech Stock Right Now?

One of the more remarkable turnaround stories from among pharmaceutical stocks has been that of Sorrento Therapeutics Inc (NASDAQ:SRNE). In February 2018, the stock had been trading at $10.65 a share to around $1.50 a share and the market cap went below $300 million as well. 

Key Triggers 

However, 2019 has been quite different and the stock surged to as much as $5.09 a share in January after it emerged that a private equity firm was prepared to acquire Sorrento for $1 billion. However, that euphoria soon passed and the stock retracted. That being said, the stock has bounced back nicely in recent times.

The stock has now gone to $8.15 a share and the market cap of Sorrento now stands at $1.67 billion. The stock has gained significantly in recent days and one of the major triggers came on Monday. The United States Food and Drug Administration granted the clearance to Sorrento to start the Phase 2 clinical trial with coronavirus patients suffering from severe breathing difficulties.

 This is a major development for Sorrento considering the commercial potential of the product. In addition to that, it also puts Sorrento in a select group of companies with Gilead Sciences, Moderna and Inovio Pharmaceuticals. 

Sorrento has had wild ups and downs over the past few years but experts believe that the latest bullish pattern could be different from the ones in the past. Hence, it could be worthwhile for investors to keep an eye on the Sorrento stock and keep track of the latest developments around it. The stock has managed to display strong momentum and it remains to be seen if it can continue to do so in the coming days. Ultimately, the forward momentum in the stock is going to be sustained through more positive developments but at this point of time, the stock has been making interesting moves.

Heat Biologics Inc (NASDAQ:HTBX) Soars 250% in 3 Weeks on Covid-19 Buzz

One of the biotech stocks that have come into focus this week is that of Heat Biologics Inc (NASDAQ:HTBX), which had traded higher on Thursday and touched $3 a share. It is interesting to note that although the current average recommendation for the stock is a moderate buy, the average price target is $4 a share and hence there could be more upside in store. 

Major Factors

In the previous 52 weeks, the Heat stock has declined by 4.65% and at the same time, the S&P500 gained 0.29%. The reason behind the company’s turnaround is grounded in its latest earnings reports. 

In the latest quarter, Heat Biologics managed to produce a profit of as much as $6.03 million and revenues rose to $0.9 million as well. At this point, it has a negative free cash flow of $5.81 million but EBITDA for the period stood at negative $5.06 million, which is not bad when compared with rivals. At this point, Heat has 82.70 million outstanding shares and a short ratio of 0.9. Another important factor to keep in mind with regards to Heat Biologics is that that company is all set to expand its operations and move into COVID 19 vaccine research. 

The company, which has primarily been involved with cancer treatments, is apparently going to use its own platform to create the vaccine. While it is true that Heat remains a loss-making company, it should be noted that there is cash available from secondary equity offerings. Hence, the funding needed for research might not be a problem. There are many companies already involved in the COVID 19 vaccine space but the potential market is so big that there could well be space for multiple products. Back in June, the company announced that the first patient had been treated with its antibody product candidate PTX 35. The product had been developed by the company subsidiary Pelican Therapeutics.

Onconova Therapeutics Inc (NASDAQ:ONTX) Rockets 150% in a Week: Are You Excited?

One of the best ways of identifying stocks is by watching the market closely and tracking the stocks which have delivered gains. One such stock could be that of Onconova Therapeutics Inc (NASDAQ:ONTX), which has rallied strongly over the course of the past week. 

Cash-Settled SAR 

During that period, the Onconova stock has rallied by as much as 150% and perhaps it could be worthwhile for investors to take a closer look at the recent developments. Back on July 10, the company announced that the compensation committee at the company approved cash-settled SAR as well as cash settle PSU to its employees. 

However, that is not the only development that needs to be taken into consideration when looking into the rally in the Onconova stock. Earlier on in July, the biopharmaceutical company published the results from the Phase 1 study of oral rigosertib in combination with standard dose azacitidine for treating patients suffering from myelodysplastic syndrome (HR-MDS) or acute myeloid leukemia (AML). 

It is a significant milestone for the company and if the product manages to produce encouraging results in the next stages of the trials, then it could propel the company to new heights. The Phase 1 study was primarily looking to determine the safety of the combination and the dosage required in the Phase 2 trial. 

While these are all important developments and perhaps had to contribute triggers to the latest rally, investors also need to consider a development from June. Back on June 23, the company announced that it started a Phase I/IIa study of oral rigosertib with Bristol-Myers Squibb’s BMY Opdivo (nivolumab) for the treatment of metastatic KRAS mutated (KRAS+) lung adenocarcinoma. 

The company’s lead candidate Rigosertib is a phase III small molecule and the initiation of the study was another major milestone for the company as it tries to further fire up its pipeline of candidates. Investors could do well to keep an eye on these varied developments over the coming weeks.

Kronos Advanced Technologies Inc. (OTCMKTS:KNOS) Stock Surges 150% in July: What’s Next?

One of the more interesting companies to have emerged in recent years is that of Kronos Advanced Technologies Inc. (OTCMKTS:KNOS) and in recent times the company has made some notable moves. The company is involved in the product development and production space and is primarily known for having revolutionised the way in which air is moved, filtered and sterilized. 

Major Triggers 

Earlier this month, the company announced the launch of the 1-800-SAFE AIR Independent Sales Rep program, by way of which the company intends to sign up as many as 200 sales representatives across the United States in the third fiscal quarter.

The move from Kronos is aimed at selling a larger volume of its products through a new sales channel altogether. Kronos went for the program in response to feedback from both customers and shareholders. Kronos is going to supply the sales representatives with marketing materials, online marketing support, and also marketing videos. 

In addition to that, the sales representatives will also get incentives which include promotional items and special pricing. At this point in time, the company is considering several online portals for the purpose of recruiting new independent sales representatives. 

While the launch of this program could prove to be a long term positive, there was another important announcement from the company this month. Kronos announced last week that it has decided to transform the company into a Public Benefit Corporation. This implies that the well being of the consumers is the primary concern of the company rather than profitability. 

The Chief Transformation Officer of Kronos Advanced stated that the company wishes to become one of the few publicly traded firms which put the interests of the customers above profit. It is a major move for the company and it remains to be seen how it is going to have an effect on its operations in the months to come.

Aptevo Therapeutics Inc (NASDAQ:APVO) Gains Momentum On a Positive News

One of the stocks that gathered momentum on Tuesday was that of the biotech firm Aptevo Therapeutics Inc (NASDAQ:APVO). It came about primarily due to the emergence of positive news regarding the company’s business. The company revealed that it has engaged the services of Piper Sandler in order to sell the royalty payment streams and milestone payouts for two of its products. 

Engages Piper Sandler to Sell its RUXIENCE and IXINITY(R) Royalty Streams & Milestones

The products in question are IXINITY and RUXIENCE. The company had announced last month that its royalty payments for RUXIENCE from pharmaceutical giant Pfizer is going to be in single digits and will take into consideration the net sales of the product in the European Union, Japan, and United States. The royalty term is for 7 years. 

On the other hand, the royalty payments for IXINITY are going to be paid by Medexus Pharmaceuticals and will take into consideration the net sales of the product in Canada and the United States. The royalty term is going to run until 2035 and payments are going to be made on a quarterly basis. 

Aptevo could also be entitled to a milestone payment of $11 million. Royalty payments can be a highly lucrative source of income for companies like Aptevo and there has been a buzz around the company ever since the company made the announcement regarding the royalty payments back on June 25. 

The Chief Executive Officer of the company Marvin L. White stated that the royalties will provide Aptevo with much needed non-dilutive cash so that it can work on its other products. He went on to state that the decision to sell the royalties and milestones to Piper Sandler is consistent with Aptevo’s quest to further strengthen its financial position. 

At the end of the day, it takes a lot of money to fund the research and development of new medicines and the latest move from Aptevo has naturally excited the market.

Ibio Inc (NYSEAMERICAN:IBIO) Contonies to Hot New Highs On Coronavirus Pandemic

Over the course of the past few months, many biotech companies have seen their stocks soar on the back of their efforts to create medicines or vaccines for the coronavirus pandemic. One such stock if Ibio Inc (NYSEAMERICAN:IBIO), which has gained as much as 490% so far as it pushes to bring a COVID 19 vaccine to the market. 

What to Expect Now?

The secret sauce for iBio is its proprietary technology called Fast Pharming that allows it to produce vaccines in bulk and hence, gives it a competitive edge over its peers. That has attracted some institutional investors to the company but ultimately its weak balance sheet remains a matter of concern. 

However, it could be worthwhile to take a closer look at Fast Pharming for anyone who is interested in iBio. The technology streamlines the production process considerably and leads to greater efficiency. Moreover, it also makes iBio an attractive proposition for those companies which are developing a COVID 19 vaccine but do not yet have the capability of scaling up production considerably. 

At this point in time, the company is collaborating with Beijing CC Pharming, Infectious Disease Research Institute. That being said, it should be borne in mind that iBio has not managed to win a contract yet. 

At this point, the company has one of the lowest market caps in the biotech sector, and on top of that its free cash flow, as well as margins, have been in the negative territory. Hence, the iBio stock has managed to do much better than its fundamentals suggest. However, the research and development investment has to be ramped up by iBio if it wishes to be a major player in the sector. Now that many companies are working on COVID 19 vaccines, iBio has emerged as a potential winner due to its Fast Pharming technology. It can churn our as much as 500 million doses of the vaccine a year and that is a significant figure. Investors could do well to keep an eye on the developments.

Five Prime Therapeutics (NASDAQ: FPRX) Hits New High on Analyst’s Optimism